Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Non-cash Items: 2021-2025

Historic Non-cash Items for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $59.8 million.

  • ARS Pharmaceuticals' Non-cash Items fell 55.40% to $59.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.8 million, marking a year-over-year decrease of 55.40%. This contributed to the annual value of $71.5 million for FY2024, which is 185.10% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Non-cash Items is $59.8 million, which was down 65.72% from $174.5 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Non-cash Items high stood at $39.4 billion for Q1 2023, and its period low was $25.1 million during Q4 2023.
  • Its 3-year average for Non-cash Items is $8.5 billion, with a median of $101.1 million in 2025.
  • In the last 5 years, ARS Pharmaceuticals' Non-cash Items soared by 86,280.30% in 2023 and then plummeted by 99.86% in 2024.
  • Over the past 5 years, ARS Pharmaceuticals' Non-cash Items (Quarterly) stood at $11.4 billion in 2021, then slumped by 99.47% to $60.4 million in 2022, then tumbled by 58.51% to $25.1 million in 2023, then spiked by 185.10% to $71.5 million in 2024, then tumbled by 55.40% to $59.8 million in 2025.
  • Its Non-cash Items stands at $59.8 million for Q3 2025, versus $174.5 million for Q2 2025 and $101.1 million for Q1 2025.